RTW Biotech Opportunities (LSE:RTW) EPS without NRI: $0.63 (TTM As of Dec. 2025)


LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
40 GF Score
Price $2.44
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities EPS without NRI?

RTW Biotech Opportunities LSE:RTW -0.41% 40 EPS without NRI is $0.63 as of Dec. 2025. GuruFocus rates LSE:RTW with a GF Score™ of 40/100. The stock has 2 warning signs investors should review. Among 834 Asset Management companies, RTW Biotech Opportunities ranks worse than 119903.96% on this metric.

RTW Biotech Opportunities's earnings per share without non-recurring items for the six months ended in Dec. 2025 was $0.75. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $0.63.

During the past 12 months, RTW Biotech Opportunities's average earnings per share (NRI) Growth Rate was 472.70% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for RTW Biotech Opportunities's EPS without NRI or its related term are showing as below:

During the past 8 years, RTW Biotech Opportunities's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -18.70% per year. The lowest was -18.70% per year. And the median was -18.70% per year.

LSE:RTW's 3-Year EPS without NRI Growth Rate is not ranked *
in the Asset Management industry.
Industry Median: 12.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

RTW Biotech Opportunities's EPS (Diluted) for the six months ended in Dec. 2025 was $0.75. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.63.

RTW Biotech Opportunities's EPS (Basic) for the six months ended in Dec. 2025 was $0.75. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.63.


RTW Biotech Opportunities  (LSE:RTW) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


RTW Biotech Opportunities EPS without NRI Related Terms


RTW Biotech Opportunities EPS without NRI Historical Data

* Premium members only.

The historical data trend for RTW Biotech Opportunities's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RTW Biotech Opportunities EPS without NRI Chart

RTW Biotech Opportunities Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial -0.27 -0.17 0.36 0.11 0.63

RTW Biotech Opportunities Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.25 -0.15 -0.12 0.75

LSE:RTW vs BLK, BX, KKR: EPS without NRI Comparison

For the Asset Management subindustry, RTW Biotech Opportunities's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RTW Biotech Opportunities PE Ratio without NRI vs Asset Management Industry

For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where RTW Biotech Opportunities's PE Ratio without NRI falls into.


LSE:RTW
40GF Score
RTW Biotech Opportunities Ltd LSE:RTW
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RTW Biotech Opportunities EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.63 mean?
RTW Biotech Opportunities (LSE:RTW) has a EPS without NRI of $0.63 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on RTW Biotech Opportunities and its competitors. According to the industry distribution chart, RTW Biotech Opportunities ranks #999999 out of 834 companies in the Asset Management industry.
Is RTW Biotech Opportunities' EPS without NRI too high?
RTW Biotech Opportunities' current EPS without NRI is $0.63. The Asset Management industry median EPS without NRI is 12.60. RTW Biotech Opportunities' value of $0.63 is 95% below this industry median. Based on the distribution chart, RTW Biotech Opportunities ranks #999999 out of 834 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, RTW Biotech Opportunities has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' EPS without NRI compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #999999 out of 834 companies for EPS without NRI. This places RTW Biotech Opportunities in the lower half of its industry. The industry median EPS without NRI is 12.60. RTW Biotech Opportunities' value of $0.63 is 95% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for an Asset Management company?
The median EPS without NRI among Asset Management companies is 12.60, based on 834 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RTW Biotech Opportunities's current EPS without NRI of $0.63 is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on RTW Biotech Opportunities and its competitors. For the Asset Management industry, the median EPS without NRI is 12.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current EPS without NRI is $0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current EPS without NRI of $0.63. The current EPS without NRI is $0.63 and 95% below the Asset Management industry median of 12.60. RTW Biotech Opportunities' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current EPS without NRI is $0.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
40GF Score

Get the complete analysis for LSE:RTW

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.44
Price